CEO of Dicerna Pharmaceuticals Inc (30-Year Financial, Insider Trades) Douglas Fambrough (insider trades) sold 139,021 shares of DRNA on 12/18/2019 at an average price of $26 a share. The total sale was $3.6 million.
Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections. Dicerna Pharmaceuticals Inc has a market cap of $1.78 billion; its shares were traded at around $26.07 with and P/S ratio of 96.20. GuruFocus has detected 1 severe warning sign with Dicerna Pharmaceuticals Inc. .
CEO Recent Trades:
- CEO Douglas Fambrough sold 139,021 shares of DRNA stock on 12/18/2019 at the average price of $26. The price of the stock has increased by 0.27% since.
CFO Recent Trades:
- CFO John B Green sold 12,500 shares of DRNA stock on 11/25/2019 at the average price of $24.95. The price of the stock has increased by 4.49% since.
Directors and Officers Recent Trades:
- Director Adam Koppel sold 1,500,000 shares of DRNA stock on 12/04/2019 at the average price of $24.68. The price of the stock has increased by 5.63% since.
- EVP & COO James B Weissman sold 20,000 shares of DRNA stock on 12/02/2019 at the average price of $26. The price of the stock has increased by 0.27% since.
- Director Peter Kolchinsky sold 643,876 shares of DRNA stock on 12/02/2019 at the average price of $24.28. The price of the stock has increased by 7.37% since.
- Director Peter Kolchinsky sold 798,600 shares of DRNA stock on 11/26/2019 at the average price of $23.53. The price of the stock has increased by 10.79% since.
- Director Peter Kolchinsky sold 1,014,193 shares of DRNA stock on 11/21/2019 at the average price of $23.34. The price of the stock has increased by 11.7% since.
For the complete insider trading history of DRNA, click here
.
